A phase I trial report tied claudin 18.2-targeted CAR T-cell therapy (satri-cel) to durable peritoneal control in three advanced gastric cancer patients with peritoneal metastases. All treated patients had confirmed high claudin 18.2 expression, with clinical and radiologic benefit and survival durations of 44 and 35 months among two of the responders. Notably, the report described rapid clearance of CAR T cells from peripheral blood by about day 30 while documenting local tissue benefit in the peritoneal space. The results support further exploration of antigen-directed T-cell therapy for gastric cancer patients where peritoneal spread historically limits durable control.
Get the Daily Brief